Overview
- Eli Lilly will invest $27 billion to construct four pharmaceutical manufacturing plants in the U.S. over the next five years, increasing its total domestic investment to $50 billion since 2020.
- The new facilities will focus on producing active pharmaceutical ingredients and injectable therapies, supporting the company’s blockbuster drugs and future pipeline developments.
- The investment is expected to create over 3,000 high-skilled jobs and 10,000 construction jobs, with site locations to be announced later this year.
- The announcement follows President Trump’s proposed 25% tariffs on pharmaceutical imports and his push for companies to reshore manufacturing to the U.S.
- CEO David Ricks emphasized the importance of extending Trump’s 2017 corporate tax cuts, which he credited as foundational to Lilly’s domestic expansion efforts.